S 2400 creates a workgroup to study blood clots and pulmonary embolisms in the state. The workgroup, appointed by the governor and legislative leaders, will include healthcare providers, patients, family members, and advocates. It must study annual incidence rates, current data collection methods, patient impacts, care standards, emerging treatments, and develop a risk surveillance system. The workgroup will issue policy recommendations within one year to improve patient awareness, surveillance in healthcare facilities (like hospitals), and written risk notices for patients. These recommendations will be published by the health department after submission.
Requires hospitals to have a registered professional nurse as a sitting and voting member of the governing entity responsible for developing a hospital's strategic plan, structure, systems, policies and programs.
Requires that general hospitals that provide mastectomy surgery, lymph node dissection or lumpectomy provide information to such patients concerning options for breast reconstruction.
Requires the administration of certain vaccines for children in accordance with regulations issued by the commissioner, utilizing generally accepted medical standards and based on recommendations of the American Academy of Pediatrics, the American Academy of Family Physicians, the American College of Obstetricians and Gynecologists, the American College of Physicians, the Advisory Committee on Immunization Practices, or other similar nationally or internationally recognized scientific organizations.
Allows for treatment costing less than $1,500 to be done without prior approval, and more clearly defines the list of "pre-authorized procedures" as a floor on treatment as opposed to its current status as a ceiling; allows non-network providers of testing to be compensated at the provider network rate negotiated by the carrier.
Relates to the establishment of regulations for administering immunizations taking into consideration the recommendations of the American Academy of Pediatrics, the American Academy of Family Physicians, the American College of Obstetricians and Gynecologists, the American College of Physicians, the advisory committee on immunization practices, any interstate body established for purposes of reviewing and making recommendations regarding immunization coverage and access, or other similar nationally or internationally recognized scientific organizations.
This bill requires health insurance plans to reimburse providers for all costs associated with administering recommended vaccinations, including both vaccine acquisition costs (based on CDC private sector rates plus 21% for shipping/storage) and full administration costs (like counseling, supplies, and nursing time, using current Medicare rates). It directly affects healthcare providers (such as clinics and doctors' offices) who administer vaccines, ensuring they are compensated for the full cost of delivery. The reimbursement applies specifically to vaccines recommended by the CDC's immunization practices committee, covering standard childhood and adult vaccines like measles, polio, and flu shots. This policy change aims to remove financial barriers for providers to offer routine vaccinations under insurance coverage.
Authorizes certain nursing students to administer certain vaccines pursuant to patient specific orders or non-patient specific orders; authorizes physicians and certified nurse practitioners to prescribe and order a patient specific order or non-patient specific order to a nursing student to administer certain vaccines.
Authorizes registered pharmacy technicians to administer the same immunizations as licensed pharmacists under direct supervision of such licensed pharmacist.
S 8334 requires health insurance plans to cover all recommended doses of the COVID-19 vaccine (SARS-CoV-2), adding it to a list of mandatory immunizations already covered by New York insurance law. This affects insurance companies, healthcare providers, and patients by mandating reimbursement for the vaccine without cost-sharing. The bill amends multiple sections of New York’s insurance and social services laws to include "severe acute respiratory syndrome coronavirus 2" in required coverage, aligning with federal standards for biological products. It applies to all insurance contracts effective January 1 after the law takes effect.